Madrigal Pharmaceuticals Stock Forward View
| MDGL Stock | USD 438.73 7.20 1.67% |
Momentum
Sell Peaked
Oversold | Overbought |
EPS Estimate Next Quarter -0.25 | EPS Estimate Current Year -5.78 | EPS Estimate Next Year 12.794 | Wall Street Target Price 667.5714 | EPS Estimate Current Quarter -0.88 |
Hype-based context for Madrigal Pharmaceuticals connects recent headlines with price response and peer activity. This sentiment summary combines Madrigal Pharmaceuticals' options data with short interest context.
Short Interest Snapshot - Madrigal Pharmaceuticals
Short interest in Madrigal Pharmaceuticals is a useful contrarian indicator. Extreme levels of short interest can precede sharp short-covering rallies if positive news surprises the market.
200 Day MA 431.33 | Short Percent 0.1904 | Short Ratio 9.55 | Shares Short Prior Month 3.6 M | 50 Day MA 487.613 |
RSI Overview - Madrigal
The Naive Prediction forecasted value of Madrigal Pharmaceuticals on the next trading day is expected to be 453.22 with a mean absolute deviation of 10.91 and the sum of the absolute errors of 665.60.Hype and Price Pattern for Madrigal Pharmaceuticals
Madrigal Pharmaceuticals' news sentiment aggregates headline tone and social media engagement to build a real-time gauge of investor psychology around Madrigal. Sentiment extremes often precede price reversals.
The correlation between Madrigal Pharmaceuticals' news sentiment and price provides a measurable basis for market timing. A strong positive correlation suggests sentiment is currently driving price; a negative one may indicate a potential reversal.
Madrigal Pharmaceuticals Implied Volatility | 0.74 |
Unlike historical volatility, which measures past price movements, Madrigal Pharmaceuticals' implied volatility is a real-time gauge of how much uncertainty the options market is pricing into Madrigal Pharmaceuticals's future price action.
The Naive Prediction forecasted value of Madrigal Pharmaceuticals on the next trading day is expected to be 453.22 with a mean absolute deviation of 10.91 and the sum of the absolute errors of 665.60.Madrigal Pharmaceuticals after-hype prediction price | $ 438.73 |
This sentiment layer is designed to be read with forecasting, technical, analyst, earnings, and momentum context.
Use Historical Fundamental Analysis of Madrigal Pharmaceuticals to cross-verify projections for Madrigal Pharmaceuticals. The historical series provides projection context.Rule 16 for the current Madrigal contract - Risk Context
Using the Rule 16 heuristic, the current implied volatility suggests an average daily move of about 0.0463% for the 2026-04-17 options. The figure is a neutral volatility reference; near $ 438.73, it implies about $ 0.2 per day.
Open Interest vs. 2026-04-17 Madrigal Options
The open interest view shows outstanding Madrigal Pharmaceuticals option contracts, providing context on participation and contract flow.
Madrigal Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Madrigal price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Madrigal using various technical indicators. When you analyze Madrigal charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Madrigal Pharmaceuticals Cash Forecast
Forecasting financial indicators like cash flow involves applying various statistical methods, techniques, and algorithms that reveal hidden trends within Madrigal Pharmaceuticals' financial statements to estimate their effects on upcoming price movements.
Cash | First Reported 2005-03-31 | Previous Quarter 295.7 M | Current Value 198.7 M | Quarterly Volatility 99.6 M |
Macro event markers
Naive Prediction Price Forecast For the 13th of March 2026
Given 90 days horizon, the Naive Prediction forecasted value of Madrigal Pharmaceuticals on the next trading day is expected to be 453.22 with a mean absolute deviation of 10.91 , mean absolute percentage error of 211.06 , and the sum of the absolute errors of 665.60 .Please note that although there have been many attempts to predict Madrigal Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Madrigal Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Madrigal Pharmaceuticals | Madrigal Pharmaceuticals Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for Madrigal Pharmaceuticals uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Madrigal Pharmaceuticals stock data series using in forecasting. Note that when a statistical model is used to represent Madrigal Pharmaceuticals stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 123.4626 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 10.9115 |
| MAPE | Mean absolute percentage error | 0.0215 |
| SAE | Sum of the absolute errors | 665.6017 |
Mean reversion in Madrigal Pharmaceuticals' price occurs when temporary dislocations - caused by sentiment extremes, news events, or liquidity shocks - correct back toward the stock's historical fair value.
After-Hype Price Density Analysis
Understanding Madrigal Pharmaceuticals' probability distribution helps investors calibrate position size to their risk tolerance. The tails of the Madrigal Pharmaceuticals distribution capture low-probability but high-impact outcomes that naive point estimates ignore.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
Using Madrigal Pharmaceuticals' historical news impact data, we estimate the likely price corridor for the next trading session after a significant headline. Madrigal Pharmaceuticals' after-hype downside and upside margins for the prediction period are 436.02 and 441.44, respectively. Note that past news reactions for Madrigal Pharmaceuticals are not guaranteed to repeat, particularly in novel market environments.
Current Value
The after-hype framework applied to Madrigal Pharmaceuticals assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Madrigal Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Madrigal Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Madrigal Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.40 | 2.71 | 1.14 | 0.12 | 11 Events | 5 Events | In 11 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
438.73 | 438.73 | 0.00 |
|
Hype Timeline
Madrigal Pharmaceuticals is now traded for 438.73. The company has historical hype elasticity of -1.14, and average elasticity to hype of competition of 0.12. Madrigal is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is about 95.42%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is now at -0.4%. %. The volatility of related hype on Madrigal Pharmaceuticals is about 937.72%, with the expected price after the next announcement by competition of 438.85. About 92.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 12.86. Madrigal Pharmaceuticals last dividend was issued on the 25th of July 2016. The company completed a 1:35 stock split on 25th of July 2016. Given the investment horizon of 90 days the next forecasted press release will be in 11 days. Use Historical Fundamental Analysis of Madrigal Pharmaceuticals to cross-verify projections for Madrigal Pharmaceuticals. The historical series provides projection context.Related Hype Analysis
Understanding how Madrigal Pharmaceuticals' direct competitors react to news events helps investors anticipate contagion effects and sector-wide sentiment shifts that may affect Madrigal Pharmaceuticals's performance.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| RNA | Atrium Therapeutics Common | -0.05 | 12 per month | 0.00 | -0.11 | 0.89 | -0.81 | 80.12 | |
| JAZZ | Jazz Pharmaceuticals PLC | 0.55 | 9 per month | 1.96 | 0.07 | 1.85 | -3.95 | 17.22 | |
| MRNA | Moderna | 4.22 | 10 per month | 3.20 | 0.23 | 10.85 | -5.95 | 23.89 | |
| CAI | Caris Life Sciences | 0.26 | 9 per month | 0.00 | -0.19 | 3.53 | -6.33 | 17.67 | |
| RYTM | Rhythm Pharmaceuticals | 0.00 | 0 per month | 0.00 | -0.10 | 3.83 | -5.14 | 11.98 | |
| ABVX | Abivax SA American | 0.00 | 0 per month | 0.00 | 0.0022 | 5.17 | -6.57 | 29.38 | |
| TECH | Bio Techne Corp | -2.67 | 7 per month | 0.00 | -0.08 | 3.56 | -4.01 | 12.41 | |
| EXEL | Exelixis | -0.85 | 10 per month | 0.00 | -0.02 | 3.61 | -3.26 | 12.62 | |
| BMRN | Biomarin Pharmaceutical | 1.43 | 7 per month | 1.44 | 0.08 | 3.15 | -2.32 | 22.06 | |
| BAX | Baxter International | 0.00 | 0 per month | 0.00 | -0.0037 | 4.80 | -3.63 | 21.62 |
Other Forecasting Options for Madrigal Pharmaceuticals
The price movement of Madrigal is a central concern for all potential investors, regardless of their level of expertise. Madrigal Stock price charts can be difficult to interpret due to the noise present in the data.Madrigal Pharmaceuticals Related Equities
The following equities are related to Madrigal Pharmaceuticals within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Madrigal Pharmaceuticals against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Madrigal Pharmaceuticals Market Strength Events
Market strength indicators applied to Madrigal Pharmaceuticals stock help investors assess the relative momentum and resilience of the security in different market environments. By using these indicators, traders can make more informed decisions about when to buy or sell Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals Risk Indicators
Risk indicator analysis for Madrigal Pharmaceuticals is essential for accurately projecting its future price trajectory. By identifying the level of risk embedded in Madrigal Pharmaceuticals' investment, investors can make informed decisions about position sizing and risk mitigation.
| Mean Deviation | 1.75 | |||
| Standard Deviation | 2.67 | |||
| Variance | 7.12 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Madrigal Pharmaceuticals
Coverage intensity for Madrigal Pharmaceuticals matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Madrigal Pharmaceuticals Short Properties
Short sentiment tied to Madrigal Pharmaceuticals matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 22.4 M | |
| Cash And Short Term Investments | 983.6 M |
More Resources for Madrigal Stock Analysis
A structured review of Madrigal Pharmaceuticals often starts with core financial statements and trend context. Ratios and trend metrics help frame Madrigal Pharmaceuticals' operating context. Key reports that frame Madrigal Pharmaceuticals Stock are listed below:Use Historical Fundamental Analysis of Madrigal Pharmaceuticals to cross-verify projections for Madrigal Pharmaceuticals. The historical series provides projection context. To learn how to invest in Madrigal Stock, please use our How to Invest in Madrigal Pharmaceuticals guide.Analysis related to Madrigal Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Earnings Share -12.86 | Revenue Per Share | Quarterly Revenue Growth 2.108 | Return On Assets | Return On Equity |
The market value of Madrigal Pharmaceuticals is measured differently than book value, which reflects Madrigal accounting equity. Madrigal Pharmaceuticals' market capitalization is 9.8 B. With a P/B ratio of 16.26, the market values Madrigal Pharmaceuticals well above its book equity. Enterprise value stands at 9.04 B. Value and price for Madrigal Pharmaceuticals are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
Note that Madrigal Pharmaceuticals' intrinsic value and market price are different measures derived from different inputs. For Madrigal Pharmaceuticals, key inputs include a P/B ratio of 16.26, a profit margin of -30.08%, ROE of -42.49%, and revenue of 958.4 M. Market price reflects the current exchange level formed by active bids and offers.